Table 1 Main neurological symptoms reported at clinical presentation in MERS cases
Study | Number of cases | Neurological symptoms, N (% of total cases) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Consciousness disturbance (irritability, lethargy, drowsiness, delirium) | Seizure | Headache | Dysphagia, dyslalia, slurred speech | Acute urinary retention | Ataxia or motor disorders | Neck stiffness | Hallucinations | Dizziness | Blurred vision | Blindness | ||
Fang Q. et al. [1] | 29 | 18/29 (62%) | 18/29 (62%) | 4/29 (14%) | 1/29 (3%) | 1/29 (3%) | 1/29 (3%) | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) | 0/29 (0%) | 0/7 (0%) |
Pan J.J. et al. [14] | 27 | 11/27 (41%) | 5/27 (19%) | 14/27 (52%) | 1/27 (4%) | 2/27 (7%) | 1/27 (4%) | 0/27 (0%) | 0/27 (0%) | 1/27 (4%) | 2/27 (7%) | 0/27 (0%) |
Tada H. et al. [2] | 15 | 12/15 (80%) | 8/15 (53%) | 2/15 (13%) | 0/15 (0%) | 0/15 (0%) | 2/15 (13%) | 1/15 (7%) | 1/15 (7%) | 2/15 (13%) | 0/15 (0%) | 1/15 (7%) |
Ka A. et al. [3] | 7 | 7/7 (100%) | 1/7 (14%) | 0/7 (0%) | 3/7 (43%) | 0/7 (0%) | 4/7 (57%) | 0/7 (0%) | 2/7 (29%) | 0/7 (0%) | 0/7 (0%) | 0/7 (0%) |
Chen W.-X. et al. [11] | 15 | 6/15 (40%) | 12/15 (80%) | 2/15 (13%) | 2/15 (13%) | 0/15 (0%) | 5/15 (33%) | 1/15 (7%) | 1/15 (7%) | 1/15 (7%) | 0/15 (0%) | 0/15 (0%) |
Yildiz A.E. et al. [13] | 8 | 2/8 (25%) | 4/8 (50%) | 1/8 (12,5%) | 2/8 (25%) | 0/8 (0%) | 1/8 (12,5%) | 2/8 (25%) | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
Winslow H. et al. [15] | 1 | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Lu P.L. et al. [16] | 15 | 3/15 (20%) | 3/15 (20%) | 3/15 (20%) | 1/15 (7%) | 0/15 (0%) | 1/15 (7%) | 0/15 (0%) | 0/15 (0%) | 3/15 (20%) | 2/15 (13%) | 0/15 (0%) |